Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2016’, provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

The report reviews pipeline therapeutics for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics and enlists all their major and minor projects

The report assesses Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Adamis Pharmaceuticals Corporation

Advaxis, Inc.

Aeterna Zentaris Inc.

Ambrx, Inc.

Amgen Inc.

AnGes MG, Inc.

Aphios Corporation

ARMO Biosciences, Inc.

Armour Therapeutics Inc.

Arno Therapeutics, Inc.

ArQule, Inc.

Arrowhead Pharmaceuticals, Inc.

Arvinas, Inc.

Asana BioSciences, LLC

Astellas Pharma Inc.

AstraZeneca Plc

ATLAB Pharma SAS

Bavarian Nordic A/S

Bayer AG

Bio-Cancer Treatment International Limited

Biscayne Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CellCentric Ltd

Celldex Therapeutics, Inc.

Corcept Therapeutics Incorporated

Corvus Pharmaceuticals, Inc.

Curevac AG

CytoVac A/S

DexTech Medical AB

Eli Lilly and Company

Enceladus Pharmaceuticals BV

Endo Pharmaceuticals Inc.

Endocyte, Inc.

Errant Gene Therapeutics, LLC

ESSA Pharma Inc

F. Hoffmann-La Roche Ltd.

Fujifilm Corporation

G1 Therapeutics, Inc.

Genentech, Inc.

Genmab A/S

Gilead Sciences, Inc.

Glactone Pharma AB

GlaxoSmithKline Plc

GTx, Inc.

Hybrigenics S.A.

Immunomedics, Inc.

Io Therapeutics, Inc.

Ionis Pharmaceuticals, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Johnson & Johnson

Jyant Technologies, Inc.

Kura Oncology, Inc.

MedImmune, LLC

Mediolanum farmaceutici S.p.A.

Medivation, Inc.

MEI Pharma, Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

NewLink Genetics Corporation

Novartis AG

Oncogenex Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

Ono Pharmaceutical Co., Ltd.

Oric Pharmaceuticals Inc

Orion Oyj

Orphagen Pharmaceuticals, Inc.

Pfizer Inc.

Progenics Pharmaceuticals, Inc.

Selexel

Sotio a.s.

Supratek Pharma Inc.

Taiho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Tesaro, Inc.

Tiltan Pharma Ltd.

Tokai Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

UbiVac, LLC

Viralytics Ltd.

Zenith Capital Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 9

Therapeutics Development 10

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 12

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 18

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 20

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 23

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 33

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 35

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 118

Drug Profiles 138

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 620

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 631

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 636

Appendix 647

List of Tables

List of Tables

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 26

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Comparative Analysis, H2 2016 27

Number of Products under Development by Companies, H2 2016 28

Number of Products under Development by Companies, H2 2016 (Contd..1) 29

Number of Products under Development by Companies, H2 2016 (Contd..2) 30

Number of Products under Development by Companies, H2 2016 (Contd..3) 31

Number of Products under Development by Companies, H2 2016 (Contd..4) 32

Number of Products under Development by Companies, H2 2016 (Contd..5) 33

Number of Products under Investigation by Universities/Institutes, H2 2016 35

Comparative Analysis by Late Stage Development, H2 2016 36

Comparative Analysis by Clinical Stage Development, H2 2016 37

Comparative Analysis by Early Stage Development, H2 2016 38

Products under Development by Companies, H2 2016 39

Products under Development by Companies, H2 2016 (Contd..1) 40

Products under Development by Companies, H2 2016 (Contd..2) 41

Products under Development by Companies, H2 2016 (Contd..3) 42

Products under Development by Companies, H2 2016 (Contd..4) 43

Products under Development by Companies, H2 2016 (Contd..5) 44

Products under Development by Companies, H2 2016 (Contd..6) 45

Products under Development by Companies, H2 2016 (Contd..7) 46

Products under Development by Companies, H2 2016 (Contd..8) 47

Products under Development by Companies, H2 2016 (Contd..9) 48

Products under Investigation by Universities/Institutes, H2 2016 49

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 50

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AB Science SA, H2 2016 51

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AbbVie Inc, H2 2016 52

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 53

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Advaxis, Inc., H2 2016 54

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Aeterna Zentaris Inc., H2 2016 55

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Ambrx, Inc., H2 2016 56

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Amgen Inc., H2 2016 57

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AnGes MG, Inc., H2 2016 58

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Aphios Corporation, H2 2016 59

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ARMO Biosciences, Inc., H2 2016 60

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Armour Therapeutics Inc., H2 2016 61

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Arno Therapeutics, Inc., H2 2016 62

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ArQule, Inc., H2 2016 63

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016 64

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Arvinas, Inc., H2 2016 65

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Asana BioSciences, LLC, H2 2016 66

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Astellas Pharma Inc., H2 2016 67

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AstraZeneca Plc, H2 2016 68

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ATLAB Pharma SAS, H2 2016 69

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Bavarian Nordic A/S, H2 2016 70

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Bayer AG, H2 2016 71

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Bio-Cancer Treatment International Limited, H2 2016 72

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 73

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 74

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 75

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by CellCentric Ltd, H2 2016 76

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Celldex Therapeutics, Inc., H2 2016 77

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Corcept Therapeutics Incorporated, H2 2016 78

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Corvus Pharmaceuticals, Inc., H2 2016 79

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Curevac AG, H2 2016 80

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by CytoVac A/S, H2 2016 81

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by DexTech Medical AB, H2 2016 82

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Eli Lilly and Company, H2 2016 83

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Enceladus Pharmaceuticals BV, H2 2016 84

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Endo Pharmaceuticals Inc., H2 2016 85

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Endocyte, Inc., H2 2016 86

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Errant Gene Therapeutics, LLC, H2 2016 87

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ESSA Pharma Inc, H2 2016 88

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 89

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Fujifilm Corporation, H2 2016 90

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by G1 Therapeutics, Inc., H2 2016 91

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Genentech, Inc., H2 2016 92

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Genmab A/S, H2 2016 93

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Gilead Sciences, Inc., H2 2016 94

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Glactone Pharma AB, H2 2016 95

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 96

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by GTx, Inc., H2 2016 97

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Hybrigenics S.A., H2 2016 98

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Immunomedics, Inc., H2 2016 99

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Io Therapeutics, Inc., H2 2016 100

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 101

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 102

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Johnson & Johnson, H2 2016 103

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Jyant Technologies, Inc., H2 2016 104

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Kura Oncology, Inc., H2 2016 105

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by MedImmune, LLC, H2 2016 106

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Mediolanum farmaceutici S.p.A., H2 2016 107

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Medivation, Inc., H2 2016 108

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by MEI Pharma, Inc., H2 2016 109

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Merck KGaA, H2 2016 110

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 111

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by NewLink Genetics Corporation, H2 2016 112

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Novartis AG, H2 2016 113

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016 114

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Oncolytics Biotech Inc., H2 2016 115

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 116

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Oric Pharmaceuticals Inc, H2 2016 117

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Orion Oyj, H2 2016 118

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 119

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Pfizer Inc., H2 2016 120

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Progenics Pharmaceuticals, Inc., H2 2016 121

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Selexel, H2 2016 122

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Sotio a.s., H2 2016 123

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Supratek Pharma Inc., H2 2016 124

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 125

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 126

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Tesaro, Inc., H2 2016 127

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Tiltan Pharma Ltd., H2 2016 128

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Tokai Pharmaceuticals, Inc., H2 2016 129

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 130

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by UbiVac, LLC, H2 2016 131

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Viralytics Ltd., H2 2016 132

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Zenith Capital Corp, H2 2016 133

Assessment by Monotherapy Products, H2 2016 134

Assessment by Combination Products, H2 2016 135

Number of Products by Stage and Target, H2 2016 137

Number of Products by Stage and Mechanism of Action, H2 2016 144

Number of Products by Stage and Route of Administration, H2 2016 151

Number of Products by Stage and Molecule Type, H2 2016 153

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects, H2 2016 636

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..1), H2 2016 637

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..2), H2 2016 638

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..3), H2 2016 639

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..4), H2 2016 640

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..5), H2 2016 641

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..6), H2 2016 642

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..7), H2 2016 643

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..8), H2 2016 644

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..9), H2 2016 645

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..10), H2 2016 646

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products, H2 2016 647

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products (Contd..1), H2 2016 648

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products (Contd..2), H2 2016 649

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products (Contd..3), H2 2016 650

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products (Contd..4), H2 2016 651

List of Figures

List of Figures

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 27

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Comparative Analysis, H2 2016 28

Number of Products under Development by Companies, H2 2016 29

Number of Products under Investigation by Universities/Institutes, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 38

Comparative Analysis by Early Stage Products, H2 2016 39

Assessment by Monotherapy Products, H2 2016 135

Number of Products by Top 10 Targets, H2 2016 137

Number of Products by Stage and Top 10 Targets, H2 2016 137

Number of Products by Top 10 Mechanism of Actions, H2 2016 144

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 144

Number of Products by Top 10 Routes of Administration, H2 2016 151

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 151

Number of Products by Top 10 Molecule Types, H2 2016 153

Number of Products by Stage and Top 10 Molecule Types, H2 2016 153

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports